Evidence map›Paper›PMID 32319336›Full record

Observational studyJournal of the American Heart Association2020

Distinct Characteristics of VEGF-D and VEGF-C to Predict Mortality in Patients With Suspected or Known Coronary Artery Disease.

Hiromichi Wada, Masahiro Suzuki, Morihiro Matsuda, Yoichi Ajiro, Tsuyoshi Shinozaki, Satoru Sakagami, Kazuya Yonezawa, Masatoshi Shimizu, Junichi Funada, Takashi Takenaka and 22 more

Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Journal of the American Heart Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. The Role of the VEGF Family in Coronary Heart Disease.Frontiers in cardiovascular medicine · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 12 institutions in 1 country.

Hiromichi WadaDivision of Translational Research National Hospital Organization Kyoto Medical Center Kyoto Japan.
Masahiro SuzukiDepartment of Clinical Research National Hospital Organization Saitama Hospital Wako Japan.
Morihiro MatsudaInstitute for Clinical Research National Hospital Organization Kure Medical Center and Chugoku Cancer Center Kure Japan.
Yoichi AjiroDivision of Clinical Research National Hospital Organization Yokohama Medical Center Yokohama Japan.
Tsuyoshi ShinozakiDepartment of Cardiology National Hospital Organization Sendai Medical Center Sendai Japan.
Satoru SakagamiDepartment of Cardiovascular Medicine National Hospital Organization Kanazawa Medical Center Kanazawa Japan.
Kazuya YonezawaDivision of Clinical Research National Hospital Organization Hakodate National Hospital Hakodate Japan.
Masatoshi ShimizuDepartment of Cardiology National Hospital Organization Kobe Medical Center Kobe Japan.
Junichi FunadaDepartment of Cardiology National Hospital Organization Ehime Medical Center Toon Japan.
Takashi TakenakaDivision of Cardiology National Hospital Organization Hokkaido Medical Center Sapporo Japan.
Yukiko MoritaDepartment of Cardiology National Hospital Organization Sagamihara National Hospital Sagamihara Japan.
Toshihiro NakamuraDepartment of Cardiology National Hospital Organization Kyushu Medical Center Fukuoka Japan.
Kazuteru FujimotoDepartment of Cardiology National Hospital Organization Kumamoto Medical Center Kumamoto Japan.
Hiromi MatsubaraDepartment of Cardiology National Hospital Organization Okayama Medical Center Okayama Japan.
Toru KatoDepartment of Clinical Research National Hospital Organization Tochigi Medical Center Utsunomiya Japan.
Takashi UnokiDivision of Translational Research National Hospital Organization Kyoto Medical Center Kyoto Japan.
Daisuke TakagiDivision of Translational Research National Hospital Organization Kyoto Medical Center Kyoto Japan.
Kyohma WadaDivision of Translational Research National Hospital Organization Kyoto Medical Center Kyoto Japan.
Miyaka WadaDivision of Translational Research National Hospital Organization Kyoto Medical Center Kyoto Japan.
Moritake IguchiDivision of Translational Research National Hospital Organization Kyoto Medical Center Kyoto Japan.
Nobutoyo MasunagaDivision of Translational Research National Hospital Organization Kyoto Medical Center Kyoto Japan.
Mitsuru IshiiDivision of Translational Research National Hospital Organization Kyoto Medical Center Kyoto Japan.
Hajime YamakageDepartment of Endocrinology, Metabolism, and Hypertension Clinical Research Institute National Hospital Organization Kyoto Medical Center Kyoto Japan.
Toru KusakabeDepartment of Endocrinology, Metabolism, and Hypertension Clinical Research Institute National Hospital Organization Kyoto Medical Center Kyoto Japan.
Akihiro YasodaClinical Research Institute National Hospital Organization Kyoto Medical Center Kyoto Japan.
Akira ShimatsuClinical Research Institute National Hospital Organization Kyoto Medical Center Kyoto Japan.
Kazuhiko KotaniDivision of Community and Family Medicine Jichi Medical University Shimotsuke Japan.
Noriko Satoh-AsaharaDepartment of Endocrinology, Metabolism, and Hypertension Clinical Research Institute National Hospital Organization Kyoto Medical Center Kyoto Japan.
Mitsuru AbeDivision of Translational Research National Hospital Organization Kyoto Medical Center Kyoto Japan.
Masaharu AkaoDivision of Translational Research National Hospital Organization Kyoto Medical Center Kyoto Japan.
Koji HasegawaDivision of Translational Research National Hospital Organization Kyoto Medical Center Kyoto Japan.
ANOX Study Investigators
Kyoto Medical Center · JPNational Hospital Organization · JPEhime Medical Center · JPJichi Medical University · JPKanazawa Medical Center · JPKobe Medical Center · JPKumamoto Medical Center · JPNational Hospital Organization Hokkaido Medical Center · JPNational Kyushu Medical Center · JPNational Sagamihara Hospital · JPSendai Medical Center · JPSuzuki (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background VEGF-D (vascular endothelial growth factor D) and VEGF-C are secreted glycoproteins that can induce lymphangiogenesis and angiogenesis. They exhibit structural homology but have differential receptor binding and regulatory mechanisms. We recently demonstrated that the serum VEGF-C level is inversely and independently associated with all-cause mortality in patients with suspected or known coronary artery disease. We investigated whether VEGF-D had distinct relationships with mortality and cardiovascular events in those patients. Methods and Results We performed a multicenter, prospective cohort study of 2418 patients with suspected or known coronary artery disease undergoing elective coronary angiography. The serum level of VEGF-D was measured. The primary outcome was all-cause death. The secondary outcomes were cardiovascular death and major adverse cardiovascular events defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. During the 3-year follow-up, 254 patients died from any cause, 88 died from cardiovascular disease, and 165 developed major adverse cardiovascular events. After adjustment for possible clinical confounders, cardiovascular biomarkers (N-terminal pro-B-type natriuretic peptide, cardiac troponin-I, and high-sensitivity C-reactive protein), and VEGF-C, the VEGF-D level was significantly associated with all-cause death and cardiovascular death but not with major adverse cardiovascular events.. Moreover, the addition of VEGF-D, either alone or in combination with VEGF-C, to the model with possible clinical confounders and cardiovascular biomarkers significantly improved the prediction of all-cause death but not that of cardiovascular death or major adverse cardiovascular events. Consistent results were observed within patients over 75 years old. Conclusions In patients with suspected or known coronary artery disease undergoing elective coronary angiography, an elevated VEGF-D value seems to independently predict all-cause mortality.

Indexed as

AgedAged, 80 and overBiomarkersCoronary AngiographyCoronary Artery DiseaseFemaleHumansIncidenceJapanMaleMiddle AgedPredictive Value of TestsPrognosisProspective StudiesRisk AssessmentRisk FactorsBiomarkersVascular Endothelial Growth Factor CVascular Endothelial Growth Factor DVEGFC protein, humanVEGFD protein, humanall‐cause deathbiomarkercardiovascular eventscoronary artery diseaseprospective cohort study

Identifiers

PMID32319336
PMCPMC7428571
OpenAlexW3017108133

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.